The US Food and Drug Administration is launching a formal assessment of small dispensers’ ability to conduct interoperable, package-level product tracing under the Drug Supply Chain Security Act.
The assessment targets pharmacies with 25 or fewer full-time employees, a group the FDA defines as small dispensers under the DSCSA framework.
The initiative comes from the agency’s Center for Drug Evaluation and Research Office of Compliance, which issued a formal notice outlining the scope of the review.
The FDA is requesting that eligible dispensers complete an assessment survey by September 22, giving the sector a defined window to respond to the agency’s data-gathering exercise.
Dispensers are permitted to designate a separate entity, such as a consultant, to complete the survey on their behalf, reducing the administrative burden on smaller operations.
The DSCSA Assessment of Small Dispensers is designed to evaluate whether this segment of the pharmacy market can meet the law’s interoperable tracing requirements across trading partners.
The FDA is specifically seeking to quantify capability gaps in exchanging package-level transaction data required for end-to-end traceability and verification across the supply chain.
Persistent barriers for smaller pharmacies include limited resources and infrastructure to support interoperable systems needed for package-level data exchange with manufacturers, distributors, and repackagers.
The FDA has granted exemptions from certain FD&C Act Section 582 requirements for eligible small dispensers and applicable partners until November 27, 2027, to enable assessment and public feedback.
No separate notification to the FDA is required for dispensers to use the exemptions, simplifying access for the small pharmacy businesses most affected by the compliance challenges.
Supply chain stakeholders may need to put interim workflows in place to accommodate dispensers that are not yet fully interoperable at the package-level tracing stage during the exemption period.
The broader DSCSA framework has long aimed to build a fully electronic, interoperable system for tracking prescription medicines through the US pharmaceutical supply chain from manufacturer to dispenser.